Clinical Trial

Trial of Cell Based Therapy for DMD

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-center, single-arm, interventional phase 1 trial to evaluate the safety and tolerability of local injection of induced pluripotent stem cell (iPSC)- derived CD54+ allogeneic muscle progenitor cells in individuals with Duchenne muscular dystrophy (DMD)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-11-14; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2025-03-21
Trial Details
NCT Number NCT06692426
Lead Sponsor Masonic Cancer Center, University of Minnesota
Collaborators: Duchenne UK, Parent Project Muscular Dystrophy
Conditions Duchenne Muscular Dystrophy
Enrollment 8 participants
Start Date 2025-03-20
Primary Completion 2027-03-03 (estimated)
Study Completion 2027-03-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-04